Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial

@article{Javidan2014SafetyAE,
  title={Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial},
  author={A. N. Javidan and H. Shahbazian and Amirhossein Emami and M. Yekaninejad and H. Emami-Razavi and Masoumeh Farhadkhani and A. Ahmadzadeh and Fazel Gorjipour},
  journal={Hematology Reports},
  year={2014},
  volume={6}
}
  • A. N. Javidan, H. Shahbazian, +5 authors Fazel Gorjipour
  • Published 2014
  • Medicine
  • Hematology Reports
  • Recombinant human erythropoietin (rHuEPO) is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patients on maintenance hemodialysis. Patients from 4 centers in Iran were enrolled for this multicenter… CONTINUE READING
    3 Citations

    Figures, Tables, and Topics from this paper

    References

    SHOWING 1-10 OF 41 REFERENCES
    Review of Patients' Responses to Epoetin Alfa Therapy
    • 2
    PDpoietin in comparison with Eprex in treatment of anemic patients on hemodialysis.
    • 5
    • PDF